Journal of Medical Screening > Volume 15, Number 1 > Pp. 36-43

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schindeler, S. Articles by Baker, D. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original Articles

High-grade cervical abnormalities and screening intervals in New South Wales, Australia

Suzanne Schindeler, Statistical Officer , Department of Health (NSW), North Sydney, Australia

Stephen Morrell, Research Fellow  , School of Public Health, University of Sydney, NSW, Australia; Epidemiologist Cancer Institute NSW, Level 1, Biomedical Building, Australian Technology Park, Eveleigh, NSW 2015, Australia

Yeqin Zuo, NSW Pap Test Register Manager , Cancer Institute NSW, Eveleigh, Australia

Deborah Baker, Research Unit Manager , Cancer Institute NSW, Eveleigh, Australia

Correspondence to: Stephen Morrell, Cancer Institute NSW, Level 1, Biomedical Building, Australian Technology Park, Eveleigh, NSW 2015, Australia; stephen.morrell{at}cancerinstitute.org.au

---

Objectives This study aims to determine the association of two versus three year screening intervals with the likelihood of detection of a high-grade cervical abnormality and cervical cancer.

Methods Data were obtained from the New South Wales (NSW) Papanicolaou (Pap) Test Register (PTR) and NSW Central Cancer Registry (CCR). Subjects were human papillomavirus (HPV) unvaccinated women aged 20–69 years who had a minimum of two Pap tests with a negative result at their first recorded Pap test (n = 1,213,295). Logistic regression was used to determine the association between screening interval and the likelihood of: (1) a cytological prediction of high-grade abnormality, defined as cervical intraepithelial neoplasia (CIN) 2 or greater; (2) a histologically confirmed high-grade abnormality; (3) a cytological prediction of cervical cancer and (4) a confirmed diagnosis of cervical cancer, controlling for potential confounders of age and socioeconomic status (SES) of area of residence.

Results For each year increase in the screening interval, the odds of a histologically confirmed high-grade abnormality increased significantly in women aged 20–29 years (odds ratio [OR] 1.24, 95% confidence interval [CI] 1.20–1.28) and in women aged 30–49 years (OR 1.11, 95% CI 1.06–1.16), but not in women aged 50–69 years (OR 1.08, 95% CI 0.89–1.32). Similar results were observed for cytologically detected high-grade abnormalities. The screening interval was significantly and positively associated with a cytological prediction of cervical cancer (OR 1.40, 95% CI 1.28–1.54) and a confirmed cervical cancer diagnosis (OR 1.66, 95% CI 1.33–2.07) in women aged 20–69 years. We estimate that if the screening interval were increased from two to three years, and the number of women participating in triennial screening participation was the same as for biennial participation in NSW, then 267 (95% CI 186–347) extra cases of high-grade abnormalities would be detected annually by cytology and 225 extra cases (95% CI 160–291) confirmed by histology, mostly confined to women aged 20–49 years. Equivalently, 2.3 (95% CI 1.8–2.8) and 1.9 (95% CI 1.5–2.4) extra cases of high-grade cytology and histology, respectively, would be expected per 1000 women with initially negative cytology if the screening interval were extended from two to three years.

Conclusion Increasing the cervical screening interval from two to three years would be expected to significantly increase the odds of detection of a high-grade abnormality for NSW women aged 20–49 years and cervical cancer for NSW women aged 20–69 years. Accordingly, our study provides evidence in support of retaining the recommended cervical screening interval at two years for HPV unvaccinated, well women.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Schindeler, M. Stephen, Z. Yeqin, and B. Deborah Erratum J Med Screen, June 1, 2009; 16(2): 104 - 105. [Full Text] [PDF]